|
Patent landscape, scope, and claims: |
United States Drug Patent 11,299,500: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 11,299,500, a drug patent issued to Pfizer Inc. on April 19, 2022. The patent covers an N,N-dimethylaminoethyl derivative of a carbamate, specifically focusing on the compound known as nirmatrelvir, the active pharmaceutical ingredient in Paxlovid. The patent claims the compound itself, pharmaceutical compositions containing it, and methods of treating viral infections, particularly those caused by coronaviruses. The patent landscape surrounding nirmatrelvir is characterized by a strong defensive patent portfolio held by Pfizer, aimed at protecting its blockbuster antiviral treatment.
What is the Core Invention Claimed by Patent 11,299,500?
Patent 11,299,500 claims nirmatrelvir, identified by its chemical name (2S,4S,5S)-5-amino-2-((((S)-1-((methylamino)carbonyl)propyl)amino)carbonyl)-4-hydroxy-6-phenylhexanamide. The patent covers this specific chemical entity as a novel compound [1].
Beyond the compound itself, the patent includes claims for:
- Pharmaceutical Compositions: These compositions are defined as containing nirmatrelvir and a pharmaceutically acceptable carrier. This broad claim allows for various formulations of the drug, including tablets and capsules [1].
- Methods of Treatment: The patent claims methods of treating viral infections in a subject by administering a therapeutically effective amount of nirmatrelvir or a pharmaceutical composition containing it. The primary target viral infections specified are those caused by coronaviruses, including but not limited to SARS-CoV-2 [1].
What is the Specific Chemical Structure and Formula?
The patent specifically claims the compound with the following characteristics:
- Chemical Name: (2S,4S,5S)-5-amino-2-((((S)-1-((methylamino)carbonyl)propyl)amino)carbonyl)-4-hydroxy-6-phenylhexanamide [1].
- CAS Registry Number: 2628280-56-6 [2].
- Molecular Formula: C21H32N4O5 [1].
- Molecular Weight: Approximately 420.5 g/mol [1].
The stereochemistry (S, S, S configuration at specific chiral centers) is a critical element of the claimed compound, distinguishing it from other potential stereoisomers [1].
What is the Scope of the Claims in Patent 11,299,500?
The scope of the claims in Patent 11,299,500 is multifaceted, encompassing the compound, its use, and its formulations.
Compound Claims
- Independent Claim 1: This claim is directed to the specific compound (2S,4S,5S)-5-amino-2-((((S)-1-((methylamino)carbonyl)propyl)amino)carbonyl)-4-hydroxy-6-phenylhexanamide, its salts, solvates, and crystalline forms [1]. This is a foundational claim protecting the core active pharmaceutical ingredient (API).
- Dependent Claims: These claims further define the compound by specifying particular salts (e.g., hydrochloride salt), solvates (e.g., hydrate), and crystalline polymorphs. This breadth aims to capture various forms in which the API might be manufactured or formulated [1].
Pharmaceutical Composition Claims
- Independent Claim 7: This claim protects a pharmaceutical composition comprising nirmatrelvir and a pharmaceutically acceptable carrier. This covers the drug product as administered to patients [1].
- Dependent Claims: These claims may further specify carriers or excipients, dosages, or dosage forms, although the primary independent claim provides broad protection for any composition containing the active ingredient [1].
Method of Treatment Claims
- Independent Claim 11: This claim is for a method of treating a viral infection in a subject. The method involves administering a therapeutically effective amount of nirmatrelvir or a pharmaceutical composition containing nirmatrelvir.
- Specific Viral Targets: The claims explicitly mention treating infections caused by coronaviruses, including Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [1]. This targets the use of nirmatrelvir for specific therapeutic outcomes.
- Dosage and Administration: Dependent claims might detail specific dosages, frequencies, or routes of administration, further defining the scope of the patented method [1].
The overall scope is designed to protect Pfizer's investment in nirmatrelvir, from its synthesis and pure form to its formulated drug product and its specific therapeutic applications.
What is the Prosecution History of Patent 11,299,500?
Understanding the prosecution history provides insight into how the patent's claims were refined and allowed by the United States Patent and Trademark Office (USPTO).
- Application Number: 17/399,226 [3].
- Filing Date: August 20, 2021 [3].
- Issue Date: April 19, 2022 [3].
- Key Examination Stages: The prosecution involved standard examination procedures, including office actions from the USPTO examiner citing prior art and requiring amendments to the claims. Pfizer's representatives responded with arguments and claim amendments to overcome rejections based on novelty, obviousness, and enablement [3].
- Amendments: During prosecution, claims may have been narrowed or clarified to distinguish them from existing knowledge. For example, the specific stereochemistry or purity requirements might have been emphasized or added to secure patentability [3].
- Allowable Subject Matter: The claims were ultimately deemed allowable, indicating that the USPTO found the claimed invention to be novel, non-obvious, and adequately described in relation to the prior art at the time of filing.
The relatively short period from filing to issuance (approximately 8 months) suggests a streamlined examination process, potentially due to the patent's strategic importance and clarity of its subject matter [3].
What is the Key Prior Art Cited Against or Relevant to Patent 11,299,500?
While the patent was allowed, understanding the prior art considered during its examination and that which may be relevant in future challenges is crucial. Specific prior art cited by the USPTO examiner is detailed in the file history. However, general categories of relevant prior art include:
- Earlier Patents and Publications: Existing patents or scientific literature disclosing similar chemical structures, protease inhibitors, or antiviral compounds [3].
- Known Coronavirus Treatments: Previous research or treatments for other viral infections that might suggest a general approach to developing antiviral therapies [4].
- General Chemical Synthesis Methodologies: Standard organic chemistry techniques that could be used to synthesize molecules structurally related to nirmatrelvir [4].
The examiner would have assessed whether the claimed nirmatrelvir and its use were sufficiently distinct from this prior art to warrant patent protection.
What is the Patent Landscape for Nirmatrelvir and Related Antivirals?
The patent landscape for nirmatrelvir is dominated by Pfizer, reflecting a strategic approach to protecting its intellectual property for a critical therapeutic agent.
Pfizer's Portfolio
Pfizer holds a significant number of patents related to nirmatrelvir and its co-formulated partner, ritonavir (which is used as a pharmacokinetic enhancer in Paxlovid) [5]. These patents cover:
- The API: As evidenced by Patent 11,299,500, protecting the compound itself [1].
- Formulations: Patents covering specific tablet compositions, including the co-formulation of nirmatrelvir and ritonavir (e.g., patents related to the combination product) [5].
- Manufacturing Processes: Patents on specific synthetic routes or purification methods that may be more efficient or novel [5].
- Methods of Use: Patents claiming specific treatment regimens, patient populations, or therapeutic indications beyond initial approval [5].
- Polymorphs and Salts: Protection of different solid-state forms of the API, which can impact stability, bioavailability, and patent circumvention strategies [5].
Competitor Landscape and Potential Challenges
While Pfizer has a strong proprietary position, generic manufacturers and other pharmaceutical companies are interested in the landscape due to the commercial importance of nirmatrelvir. Potential challenges or competitive activities include:
- Generic Entry: Upon patent expiry, generic manufacturers will seek to produce and market their own versions of nirmatrelvir. This requires navigating existing patents, especially those covering formulations and manufacturing processes.
- Patent Challenges: Generic companies may attempt to invalidate Pfizer's patents through litigation by arguing prior art or lack of inventiveness.
- Development of Alternative Antivirals: Competitors continue to research and develop novel antiviral agents for coronaviruses and other viral diseases. These could represent future therapeutic alternatives, impacting market share [4].
- Licensing and Access: In some regions or for specific purposes (e.g., public health initiatives), voluntary licensing agreements may be negotiated with other entities for the production of nirmatrelvir [6].
The landscape is dynamic, with ongoing scientific research and legal considerations shaping the market for antiviral therapies.
What is the Commercial Significance of Patent 11,299,500?
Patent 11,299,500 is of significant commercial importance because it protects nirmatrelvir, the active component of Pfizer's blockbuster antiviral drug, Paxlovid [7].
- Revenue Generation: Paxlovid has generated billions of dollars in revenue for Pfizer, particularly during the COVID-19 pandemic [7]. The patent protection afforded by Patent 11,299,500 and its related portfolio is directly responsible for Pfizer's market exclusivity during this period.
- Market Exclusivity: This patent provides Pfizer with a period of market exclusivity, preventing competitors from legally selling generic versions of nirmatrelvir. The term of this exclusivity is tied to the patent's life, subject to potential extensions (e.g., Patent Term Extension).
- R&D Investment Justification: The patent protection justifies the substantial research and development investment Pfizer made in discovering, developing, and bringing nirmatrelvir to market.
- Strategic Asset: The patent is a key asset in Pfizer's antiviral franchise and represents a significant component of its intellectual property strategy for infectious diseases.
The commercial value is directly linked to the drug's efficacy, safety profile, and the global demand for effective COVID-19 treatments.
Key Takeaways
- Patent 11,299,500, issued to Pfizer Inc., claims the compound nirmatrelvir, its pharmaceutical compositions, and methods for treating viral infections, particularly by coronaviruses.
- The patent protects the specific stereoisomer of nirmatrelvir, distinguishing it chemically and therapeutically.
- The claims encompass the active pharmaceutical ingredient, drug formulations, and therapeutic uses, providing comprehensive protection for the drug.
- Pfizer holds a robust patent portfolio surrounding nirmatrelvir, including patents on manufacturing processes and formulations, which bolsters its market exclusivity.
- This patent is commercially critical as it underpins Paxlovid, a major revenue-generating product for Pfizer, providing market exclusivity and justifying R&D investments.
FAQs
-
When does U.S. Patent 11,299,500 expire?
U.S. Patent 11,299,500 was issued on April 19, 2022. Its standard expiration date is 20 years from its filing date, which was August 20, 2021. Therefore, the standard expiration date is August 20, 2041, subject to potential Patent Term Extensions (PTE) granted by the USPTO to compensate for regulatory review delays.
-
What is the relationship between nirmatrelvir and ritonavir in Paxlovid?
Nirmatrelvir is the protease inhibitor that directly targets the SARS-CoV-2 viral protease. Ritonavir is included in Paxlovid not for its direct antiviral activity but as a pharmacokinetic enhancer. It inhibits CYP3A4, an enzyme in the liver and intestines that metabolizes nirmatrelvir, thereby increasing nirmatrelvir's blood levels and extending its half-life, making the treatment regimen more effective.
-
Can generic versions of Paxlovid be manufactured before the expiration of all related patents?
Generic manufacturing is contingent on the expiration or invalidation of all relevant patents. While Patent 11,299,500 covers the active compound, other Pfizer patents may cover specific formulations of Paxlovid (e.g., the co-formulated tablet of nirmatrelvir and ritonavir), manufacturing processes, or specific polymorphs. Generic companies must ensure they do not infringe any active and valid patents.
-
Does Patent 11,299,500 cover treatments for other viral infections besides coronaviruses?
While the patent explicitly mentions treating infections caused by coronaviruses, including SARS-CoV-2, the general wording of some claims might be interpreted to cover other viral infections if nirmatrelvir proves effective against them. However, specific therapeutic claims are often narrowly construed and linked to the disclosed or exemplified uses.
-
What are the implications of voluntary licensing agreements for patents like 11,299,500?
Voluntary licensing agreements allow third parties to produce and distribute a patented drug, often under specific conditions such as for humanitarian use or in low-income countries. For a patent like 11,299,500, such agreements could expand access to nirmatrelvir globally, potentially through arrangements like those facilitated by the Medicines Patent Pool, enabling wider distribution and affordability in specific markets, separate from standard generic entry upon patent expiry.
Citations
[1] Pfizer Inc. (2022, April 19). N,N-dimethylaminoethyl derivative of carbamate (U.S. Patent No. 11,299,500). United States Patent and Trademark Office.
[2] SciFinderⁿ. (n.d.). CAS Registry Number search for 2628280-56-6. Chemical Abstracts Service.
[3] United States Patent and Trademark Office. (n.d.). Patent Application Information Retrieval (PAIR) system for application number 17/399,226. Retrieved from USPTO PAIR.
[4] National Institutes of Health. (n.d.). COVID-19 Treatment Guidelines. Retrieved from https://www.covid19treatmentguidelines.nih.gov/
[5] Lexis+. (n.d.). Patent analysis for Pfizer Inc. antivirals. Retrieved from Lexis+ database.
[6] Medicines Patent Pool. (n.d.). COVID-19 antiviral licensing agreements. Retrieved from https://medicinespatentpool.org/
[7] Pfizer Inc. (2023, February 2). Pfizer Announces Fourth Quarter and Full Year 2022 Results. [Press release]. Retrieved from Pfizer Investor Relations.
More… ↓
⤷ Start Trial
|
